Targeted Treatment for Gastrointestinal Stromal Tumors
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
Progress Against Cancer
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the...
The FDA approved the immune checkpoint inhibitor pembrolizumab in combination with the molecularly targeted therapeutic lenvatinib for women with advanced endometrial cancer.
The FDA has approved a molecularly targeted therapeutic for treating certain adults with a rare blood cancer called myelofibrosis.
The molecularly targeted therapeutic entrectinib is the second therapeutic of its kind approved by the FDA for use based on tumor biomarker rather than the site where the cancer originated. The U.S. Food and...
The FDA approved the molecularly targeted therapeutic entrectinib to treat certain patients with metastatic non–small cell lung cancer. Learn more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More